EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Seamless monotherapy-combination phase I dose-escalation model-based design

Libby Daniells iD, Thomas Jaki, Alimu Dayimu iD, Nikos Demiris, Basu Bristi, Stefan Symeonides iD, Pavel Mozgunov iD

Clinical Trials · 2025

DOI: 10.1177/17407745251350604 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Trials, 2025. Verfasst von Libby Daniells und 6 weiteren Autor:innen. Beteiligte Einrichtung: MRC Biostatistics Unit, University of Cambridge, Cambridge, UK. Hauptthemen laut MEDLINE: Clinical Trials, Phase I as Topic, Research Design, Antineoplastic Combined Chemotherapy Protocols, Antineoplastic Agents. Die Arbeit nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medical Research Council, NIHR Advanced Fellowship.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Phase I dose-escalation studies for a single-agent and combination of anti-cancer agents have explored various model-based designs to guide identification of a maximum tolerated dose and recommended phase II dose. This work describes a parallel approach to dose escalation to expedite identification of maximum tolerated doses both for an anti-cancer agent as monotherapy and in combination with another agent. We develop a three-parameter Bayesian logistic regression model that allows for more efficient use of information between monotherapy and combination parts of the study. The model allows the monotherapy and combination data to drive dose escalation of the combination of treatments, reflecting the known dose-toxicity relationship between the monotherapy and combination setting. Through a thorough simulation study in which the proposed model is compared to two comparative approaches, the three-parameter Bayesian logistic regression model is shown to accurately select doses in the target toxicity interval, performing similar to comparative approaches in terms of proportion of target dose/combination selection, while more than halving the proportion of doses selected that were greater than the target toxicity, thereby improving safety concerns.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Clinical Trials, Phase I as TopicResearch DesignAntineoplastic Combined Chemotherapy ProtocolsAntineoplastic AgentsNeoplasmsHumansBayes TheoremMaximum Tolerated DoseDose-Response Relationship, DrugLogistic ModelsComputer Simulation

Stichwörter der Autor:innen

Dose-findingcombination study

Substanzen

Antineoplastic Agents

Autor:innen und Institutionen

  • MRC Biostatistics Unit, University of Cambridge, Cambridge, UK.
  • Faculty of Informatics and Data Science, University of Regensburg, Regensburg, Germany.
  • Clinical Trials Unit, Cancer Theme, University of Cambridge, Cambridge, UK.
  • Department of Oncology, University of Cambridge, Cambridge, UK.
  • Edinburgh Experimental Cancer Medicine Centre, Institute of Genetics and Cancer, The University of Edinburgh, Edinburgh, UK.
  • Centre for Drug Development, Cancer Research UK, London, UK.

ORCID-Profile: Libby Daniells, Alimu Dayimu, Stefan Symeonides, Pavel Mozgunov

Förderung

  • Medical Research Council
  • NIHR Advanced Fellowship

Zitieren

APA

Daniells, L., Jaki, T., Dayimu, A., Demiris, N., Bristi, B., Symeonides, S., & Mozgunov, P. (2025). Seamless monotherapy-combination phase I dose-escalation model-based design. Clinical Trials. https://doi.org/10.1177/17407745251350604

Vancouver

Daniells L, Jaki T, Dayimu A, Demiris N, Bristi B, Symeonides S, et al. Seamless monotherapy-combination phase I dose-escalation model-based design. Clinical Trials. 2025. doi:10.1177/17407745251350604

BibTeX
@article{Daniells2025,
  author = {Daniells, Libby and Jaki, Thomas and Dayimu, Alimu and Demiris, Nikos and Bristi, Basu and Symeonides, Stefan and Mozgunov, Pavel},
  title = {Seamless monotherapy-combination phase I dose-escalation model-based design},
  journal = {Clinical Trials},
  year = {2025},
  doi = {10.1177/17407745251350604}
}
Kostenlos starten →